Brain tumors: MR imaging with gadolinium-DTPA.

Abstract

Magnetic resonance (MR) imaging was performed on 40 patients with intracranial tumors, before and after intravenous administration of gadolinium-DTPA (Gd-DTPA). Precontrast studies included a comprehensive protocol of spin-echo sequences. Tumors were visualized on precontrast images either directly or indirectly by anatomic distortion caused by the mass. However, differentiation of the tumor from adjacent tissues was possible in only 17 of 40 cases. Delineation of the tumor was best on precontrast, T2-weighted images. After administration of Gd-DTPA (0.1 mmol/kg), increased signal intensity from the tumor was observed in all patients. The localized increase in signal intensity in the tumor considerably improved the tumor delineation in 36 of 40 patients. Whereas most of the meningiomas, neuromas, and adenomas could be delineated prior to administration of contrast material if appropriate pulse sequences were applied, glioblastomas and intracranial metastases required Gd-DTPA administration for diagnostically sufficient tumor display.

Apparent Diffusion Coefficient of Glial Neoplasms: Correlation with Fluorodeoxyglucose–Positron-Emission Tomography and Gadolinium-Enhanced MR Imaging

“…2 Routine Gd-enhanced MR imaging plays a crucial role in the assessment of gliomas. 6 However, Gd-enhancement has limitations in that it identifies the presence of an abnormal blood-brain barrier, 7 rather than physiology, histology, genetic aberrations, or molecular events. With the advent of molecular and genetic treatment strategies aimed at gliomas, 3,4 more sophisticated radiologic methods are necessary to follow these tumors, including assessment of therapy and the detection of tumor progression.…”

Evaluation of different cerebral mass lesions by perfusion‐weighted MR imaging

“…Conventional techniques are adequate for detecting intracranial masses, but cannot be used to grade tumors and discriminate lesions from each other (2). In addition, these techniques are rather insensitive for discriminating tumoral lesions from postoperative abnormal pathologic tissue or necrosis after radiotherapy.…”

T1 and T2 relaxation times on gadolinium-diethylenetriaminepentaacetic acid enhanced magnetic resonance images of brain tumors.

“…The mechanism of the enhancement was suggested that the injected Gd-DTPA diffuses to the interstitial tissue of brain tumor through the destroyed blood-brain barrier, then the accumulated Gd-DTPA in the tumor tissue shortens the proton T1 and T2 (Carr et al 1984;Felix et al 1985;Graif et al 1985).…”

“…A paramagnetic contrast agent, gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA), has successfully increased the sensitivity for detection of cerebral abnormalities in magnetic resonance (MR) images, and given the characterization of pathologic conditions (Carr et al 1984;Felix et al 1985; Graif et al 1985). According to the clinical use of the contrast agent for the enhancement in MR images, quantitative analysis is desirable to consider the relation between Gd-DTPA enhancement and patho-physiologic tissue characteristics (Graif et al 1985).…”